{"id":949812,"date":"2026-04-08T08:07:02","date_gmt":"2026-04-08T12:07:02","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/urogen-launches-lg-utuc-luminaries-initiative-recognizing-excellence-and-leadership-in-treatment-of-patients-with-low-grade-upper-tract-urothelial-cancer\/"},"modified":"2026-04-08T08:07:02","modified_gmt":"2026-04-08T12:07:02","slug":"urogen-launches-lg-utuc-luminaries-initiative-recognizing-excellence-and-leadership-in-treatment-of-patients-with-low-grade-upper-tract-urothelial-cancer","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/urogen-launches-lg-utuc-luminaries-initiative-recognizing-excellence-and-leadership-in-treatment-of-patients-with-low-grade-upper-tract-urothelial-cancer\/","title":{"rendered":"UroGen Launches LG-UTUC Luminaries Initiative Recognizing Excellence and Leadership in Treatment of Patients with Low-Grade Upper Tract Urothelial Cancer"},"content":{"rendered":"<div class=\"mw_release\">\n<p>PRINCETON, N.J., April  08, 2026  (GLOBE NEWSWIRE) &#8212; UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced the launch of its \u201cLG-UTUC Luminaries\u201d initiative, recognizing clinicians and institutions demonstrating leadership, expertise, and a commitment to advancing low\u2011grade upper tract urothelial cancer (LG\u2011UTUC) care.<\/p>\n<p>LG\u2011UTUC is a rare form of cancer affecting an estimated 6,000-7,000 patients each year in the U.S., which represents approximately 40% of patients diagnosed in the U.S. annually with UTUC. While typically noninvasive, it often recurs and may require repeated endoscopic procedures or radical surgery to remove the kidney and ureter, underscoring a continued need for guideline-recommended kidney\u2011sparing care approaches.<\/p>\n<p>\u201cThrough the LG-UTUC Luminaries initiative, we are honored to recognize the clinicians and institutions redefining what is possible for patients living with LG-UTUC,\u201d said Liz Barrett, President and Chief Executive Officer of UroGen. \u201cBy elevating these leaders, we aim to inspire broader adoption of evidence-based, kidney-sparing care, strengthen collaboration across the urology community, and accelerate progress toward a future where patients with this highly recurrent disease have better outcomes and a better care experience.\u201d<\/p>\n<p>The LG-UTUC Luminaries initiative recognizes clinicians and institutions working to achieve excellence in LG-UTUC care. Honorees have extensive experience with LG-UTUC and are actively involved in treatment, research, and peer-to-peer education. Institutional recipients are distinguished by established, guideline-aligned care pathways spanning diagnosis, treatment, and long-term surveillance, as well as strong commitments to physician training, research participation, and comprehensive patient support.<\/p>\n<p>UroGen recognizes Saum Ghodoussipour, MD, Director, Bladder and Urothelial Cancer Program, Rutgers Cancer Institute, and Associate Professor of Surgery, Rutgers Robert Wood Johnson Medical School, as the first recipient of this flagship LG-UTUC Luminaries recognition\u2014an honor that will continue to be presented to physicians and institutions dedicated to helping shape the future of kidney-sparing management in LG-UTUC.<\/p>\n<p>\u201cI\u2019m truly honored to receive this recognition,\u201d said Dr. Saum Ghodoussipour, Director of the Bladder and Urothelial Cancer Program at Rutgers Cancer Institute and Associate Professor of Surgery at Rutgers Robert Wood Johnson Medical School, NJ. \u201cThis distinction reflects the dedication of our entire multidisciplinary team at Rutgers Cancer Institute, whose commitment to advancing education, research, and patient-centered care continues to drive progress for individuals living with LG-UTUC. I\u2019d especially like to recognize Dr. Vignesh Packiam, Director of Clinical and Translational Research in Urologic Oncology and Associate Professor of Surgery at Rutgers Robert Wood Johnson Medical School, whose leadership and contributions have been instrumental in shaping our program. Together, we remain committed to improving outcomes through collaboration, innovation, and a steadfast focus on our patients.\u201d<\/p>\n<p>\n        <strong>About the LG-UTUC Luminaries Initiative<\/strong><br \/>\n        <br \/>The LG-UTUC Luminaries initiative is UroGen\u2019s effort to recognize and collaborate with leading clinicians and institutions advancing care for patients with low-grade upper tract urothelial cancer. By highlighting clinical leadership and fostering collaboration across the urology community, the initiative supports continued progress in kidney-sparing care and efforts to improve outcomes in this rare and highly recurrent disease.<\/p>\n<p>\n        <strong>About\u00a0UroGen Pharma Ltd.\u00a0<\/strong><br \/>\n        <br \/>UroGen is a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers because patients deserve better options. UroGen has developed\u00a0<em>RTGel<\/em><sup><em>\u00ae<\/em><\/sup>\u00a0reverse-thermal hydrogel, a proprietary sustained-release, hydrogel-based platform technology that has the potential to improve the therapeutic profiles of existing drugs. UroGen\u2019s sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. UroGen is headquartered in\u00a0Princeton, NJ\u00a0with operations in\u00a0Israel. Visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Hsyhan3_q0UKXPKlHu_-s9_pK3SDBmrEMIqWiI2kgskWjSOEytXRuPkd-Ll3qUV2iZMtmCWq5Q-9qPZdQV-fh7vnqxORbTbG4DtsBhiV4hdt-rhdVLrlu1woDYb2LeVVqVcahHHes54NYGt2Z_P3nXRidJ4-SZ5R3KdUeolhlQezGvG_EtRs8AgkUprPnExi7q-DsI4OTSqzcTe8dDR-UdsjeEJfGVnLkcBNw3tTqwlSiACxZ80kig3g30ePvanugLjIb-ftOIu_UBznjX3D9rSwcEq3uoghY_IlKHU2Xn1YJPerjJ2fWpQYRXCz6rG81Q5ogkB-gPuH6ld4-ZBRraHXBVXG6oPRY9lulkBkIx_TDKxI8Wl5oD_y8IsE_PqvjxtcT9J4XfdEEo4pyKaq5UMq68sSSsf2J1ajDtIknvzyCOeuXbqZC-uTwXTzlJEe5z30d95Uv56Ex2GpZgMgzkSxSRB5nLnLJGeVQPJlt6TzBgekLP2yeit7-Pra59Vx8oORJXS8u6ClC-lqxhbF5RxanOpC9oPeBHpEXQdXwJX1hB7XP-ZgBSJ51Ni_lreiuSd4HNhtyclZMYjvTnTFnsrnFKRCLLQJxLuRo5GvRkZ8VHfK33wZFS62nW5c_lMXMrLnLwDFMGqOOCTyoc4L41u5GG569JzF66Cz0Umj_19QIwTbZAcfbmHSNcts4rHD_5g4N-wttthRcmeN3K8NIE_RG4nhbo0aZy5oxJAYhj6YpznTq5Pl2iDPi0GhA11J4YSf42OqkYh73cGtUvhsMfaK8NUMECDeR3sh0CeVqVIbR1NGQnRuC0Ctgal0w2JcBqfQ8GH8Wsc3OdF1m-itaUQMt-XCrX6PDpchSongsHcVg_JnwF3MK_pNxtxSKcSpBtOe49slYNizCM0BW1O8T-Vq-MSjn1b8pSz6dDF2h4lP15WYJMkIMKxTdM_OW_usQuJZ_HKCqtY8ld3HtJ0xV8PanigliL4FwWeeOUOhPo_BXRWYKjLM7zRJVoXy6vpWfIBA2pMy8ioX22v2SwEOg5GXNeKoPFB1SG8aLlwwzxEvHdE-XemG3-EyQivKfwp9\" rel=\"nofollow\" target=\"_blank\"><strong>www.UroGen.com<\/strong><\/a>\u00a0to learn more or follow us on X, @UroGenPharma.<\/p>\n<p>\n        <strong>INVESTOR CONTACT:<\/strong><br \/>\n        <br \/>Vincent Perrone<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=FFarF82FDBfYGesL1AXnzHTZQPHllTBvAMp0flBZ1a81wzsLq3p_lxNwoN5fo2gvrhRNnNe_wmlh7sTXRo-BS_dicR7hZmuJZ1fmVEcEO28eeGmh684QMIKK2wtvhaqI87qAov-DvtLvNcEmxuqHQUaISil_l4JV3D9Ygp_h_HeeOfYGXfov6ZgmvtNyfNiHIEkJm1SK8sCeyHsZlg6DvVi2IMXWGiSkPNPd6gJxspogOt2kdUkdXrmNKHtfqXAuBF3-nWK2b4HkmjFNJiICbZ_mO2lr_eVcUCWDNeoip4k=\" rel=\"nofollow\" target=\"_blank\">vincent.perrone@urogen.com<\/a><br \/>(609) 460-3588 Ext. 1093<\/p>\n<p>\n        <strong>MEDIA CONTACT:<\/strong><br \/>\n        <br \/>Cindy Romano<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ABPA2StJOPFNYo5iRWCQArcbexkHyujSFNfIiLUy6K-vliZnQHgNuV955h48wGv1E-yuqRr-RtFH7vJoUDoNMBdQ_dvnqAlBch9yfsjHTJ9Zt8s2sDKcz-QGWM_oEPWOBaOy4BAZclqa-w0CqEBCrISQg3hlIsO34w8nldgg5G-hBvRerjEqhyzLDkJ84vxxqPz-96bACbPP4QiAIFoDAS0IqhRqUl-HFp_INd6Jr0AdY0AONqyMb0torwWQ6BHxndEdqjJVGajoGdq9Uf_DKg==\" rel=\"nofollow\" target=\"_blank\">Cindy.romano@urogen.com<\/a><br \/>(609) 460-3566 Ext. 1083<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY4NTg0MiM3NTI0MjQ4IzIwMjkwMTk=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/ZjJjM2U0NjQtN2ZmZC00MTMwLTk4MTYtOGJjMTU3N2Y0ZmQzLTEwNDA1OTAtMjAyNi0wNC0wOC1lbg==\/tiny\/UroGen-Pharma-Ltd-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>PRINCETON, N.J., April 08, 2026 (GLOBE NEWSWIRE) &#8212; UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced the launch of its \u201cLG-UTUC Luminaries\u201d initiative, recognizing clinicians and institutions demonstrating leadership, expertise, and a commitment to advancing low\u2011grade upper tract urothelial cancer (LG\u2011UTUC) care. LG\u2011UTUC is a rare form of cancer affecting an estimated 6,000-7,000 patients each year in the U.S., which represents approximately 40% of patients diagnosed in the U.S. annually with UTUC. While typically noninvasive, it often recurs and may require repeated endoscopic procedures or radical surgery to remove the kidney and ureter, underscoring a continued need for guideline-recommended kidney\u2011sparing care approaches. \u201cThrough the LG-UTUC &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/urogen-launches-lg-utuc-luminaries-initiative-recognizing-excellence-and-leadership-in-treatment-of-patients-with-low-grade-upper-tract-urothelial-cancer\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;UroGen Launches LG-UTUC Luminaries Initiative Recognizing Excellence and Leadership in Treatment of Patients with Low-Grade Upper Tract Urothelial Cancer&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-949812","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>UroGen Launches LG-UTUC Luminaries Initiative Recognizing Excellence and Leadership in Treatment of Patients with Low-Grade Upper Tract Urothelial Cancer - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/urogen-launches-lg-utuc-luminaries-initiative-recognizing-excellence-and-leadership-in-treatment-of-patients-with-low-grade-upper-tract-urothelial-cancer\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"UroGen Launches LG-UTUC Luminaries Initiative Recognizing Excellence and Leadership in Treatment of Patients with Low-Grade Upper Tract Urothelial Cancer - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PRINCETON, N.J., April 08, 2026 (GLOBE NEWSWIRE) &#8212; UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced the launch of its \u201cLG-UTUC Luminaries\u201d initiative, recognizing clinicians and institutions demonstrating leadership, expertise, and a commitment to advancing low\u2011grade upper tract urothelial cancer (LG\u2011UTUC) care. LG\u2011UTUC is a rare form of cancer affecting an estimated 6,000-7,000 patients each year in the U.S., which represents approximately 40% of patients diagnosed in the U.S. annually with UTUC. While typically noninvasive, it often recurs and may require repeated endoscopic procedures or radical surgery to remove the kidney and ureter, underscoring a continued need for guideline-recommended kidney\u2011sparing care approaches. \u201cThrough the LG-UTUC &hellip; Continue reading &quot;UroGen Launches LG-UTUC Luminaries Initiative Recognizing Excellence and Leadership in Treatment of Patients with Low-Grade Upper Tract Urothelial Cancer&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/urogen-launches-lg-utuc-luminaries-initiative-recognizing-excellence-and-leadership-in-treatment-of-patients-with-low-grade-upper-tract-urothelial-cancer\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-08T12:07:02+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY4NTg0MiM3NTI0MjQ4IzIwMjkwMTk=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/urogen-launches-lg-utuc-luminaries-initiative-recognizing-excellence-and-leadership-in-treatment-of-patients-with-low-grade-upper-tract-urothelial-cancer\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/urogen-launches-lg-utuc-luminaries-initiative-recognizing-excellence-and-leadership-in-treatment-of-patients-with-low-grade-upper-tract-urothelial-cancer\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"UroGen Launches LG-UTUC Luminaries Initiative Recognizing Excellence and Leadership in Treatment of Patients with Low-Grade Upper Tract Urothelial Cancer\",\"datePublished\":\"2026-04-08T12:07:02+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/urogen-launches-lg-utuc-luminaries-initiative-recognizing-excellence-and-leadership-in-treatment-of-patients-with-low-grade-upper-tract-urothelial-cancer\\\/\"},\"wordCount\":643,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/urogen-launches-lg-utuc-luminaries-initiative-recognizing-excellence-and-leadership-in-treatment-of-patients-with-low-grade-upper-tract-urothelial-cancer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY4NTg0MiM3NTI0MjQ4IzIwMjkwMTk=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/urogen-launches-lg-utuc-luminaries-initiative-recognizing-excellence-and-leadership-in-treatment-of-patients-with-low-grade-upper-tract-urothelial-cancer\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/urogen-launches-lg-utuc-luminaries-initiative-recognizing-excellence-and-leadership-in-treatment-of-patients-with-low-grade-upper-tract-urothelial-cancer\\\/\",\"name\":\"UroGen Launches LG-UTUC Luminaries Initiative Recognizing Excellence and Leadership in Treatment of Patients with Low-Grade Upper Tract Urothelial Cancer - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/urogen-launches-lg-utuc-luminaries-initiative-recognizing-excellence-and-leadership-in-treatment-of-patients-with-low-grade-upper-tract-urothelial-cancer\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/urogen-launches-lg-utuc-luminaries-initiative-recognizing-excellence-and-leadership-in-treatment-of-patients-with-low-grade-upper-tract-urothelial-cancer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY4NTg0MiM3NTI0MjQ4IzIwMjkwMTk=\",\"datePublished\":\"2026-04-08T12:07:02+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/urogen-launches-lg-utuc-luminaries-initiative-recognizing-excellence-and-leadership-in-treatment-of-patients-with-low-grade-upper-tract-urothelial-cancer\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/urogen-launches-lg-utuc-luminaries-initiative-recognizing-excellence-and-leadership-in-treatment-of-patients-with-low-grade-upper-tract-urothelial-cancer\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/urogen-launches-lg-utuc-luminaries-initiative-recognizing-excellence-and-leadership-in-treatment-of-patients-with-low-grade-upper-tract-urothelial-cancer\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY4NTg0MiM3NTI0MjQ4IzIwMjkwMTk=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY4NTg0MiM3NTI0MjQ4IzIwMjkwMTk=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/urogen-launches-lg-utuc-luminaries-initiative-recognizing-excellence-and-leadership-in-treatment-of-patients-with-low-grade-upper-tract-urothelial-cancer\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"UroGen Launches LG-UTUC Luminaries Initiative Recognizing Excellence and Leadership in Treatment of Patients with Low-Grade Upper Tract Urothelial Cancer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"UroGen Launches LG-UTUC Luminaries Initiative Recognizing Excellence and Leadership in Treatment of Patients with Low-Grade Upper Tract Urothelial Cancer - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/urogen-launches-lg-utuc-luminaries-initiative-recognizing-excellence-and-leadership-in-treatment-of-patients-with-low-grade-upper-tract-urothelial-cancer\/","og_locale":"en_US","og_type":"article","og_title":"UroGen Launches LG-UTUC Luminaries Initiative Recognizing Excellence and Leadership in Treatment of Patients with Low-Grade Upper Tract Urothelial Cancer - Market Newsdesk","og_description":"PRINCETON, N.J., April 08, 2026 (GLOBE NEWSWIRE) &#8212; UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced the launch of its \u201cLG-UTUC Luminaries\u201d initiative, recognizing clinicians and institutions demonstrating leadership, expertise, and a commitment to advancing low\u2011grade upper tract urothelial cancer (LG\u2011UTUC) care. LG\u2011UTUC is a rare form of cancer affecting an estimated 6,000-7,000 patients each year in the U.S., which represents approximately 40% of patients diagnosed in the U.S. annually with UTUC. While typically noninvasive, it often recurs and may require repeated endoscopic procedures or radical surgery to remove the kidney and ureter, underscoring a continued need for guideline-recommended kidney\u2011sparing care approaches. \u201cThrough the LG-UTUC &hellip; Continue reading \"UroGen Launches LG-UTUC Luminaries Initiative Recognizing Excellence and Leadership in Treatment of Patients with Low-Grade Upper Tract Urothelial Cancer\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/urogen-launches-lg-utuc-luminaries-initiative-recognizing-excellence-and-leadership-in-treatment-of-patients-with-low-grade-upper-tract-urothelial-cancer\/","og_site_name":"Market Newsdesk","article_published_time":"2026-04-08T12:07:02+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY4NTg0MiM3NTI0MjQ4IzIwMjkwMTk=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/urogen-launches-lg-utuc-luminaries-initiative-recognizing-excellence-and-leadership-in-treatment-of-patients-with-low-grade-upper-tract-urothelial-cancer\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/urogen-launches-lg-utuc-luminaries-initiative-recognizing-excellence-and-leadership-in-treatment-of-patients-with-low-grade-upper-tract-urothelial-cancer\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"UroGen Launches LG-UTUC Luminaries Initiative Recognizing Excellence and Leadership in Treatment of Patients with Low-Grade Upper Tract Urothelial Cancer","datePublished":"2026-04-08T12:07:02+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/urogen-launches-lg-utuc-luminaries-initiative-recognizing-excellence-and-leadership-in-treatment-of-patients-with-low-grade-upper-tract-urothelial-cancer\/"},"wordCount":643,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/urogen-launches-lg-utuc-luminaries-initiative-recognizing-excellence-and-leadership-in-treatment-of-patients-with-low-grade-upper-tract-urothelial-cancer\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY4NTg0MiM3NTI0MjQ4IzIwMjkwMTk=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/urogen-launches-lg-utuc-luminaries-initiative-recognizing-excellence-and-leadership-in-treatment-of-patients-with-low-grade-upper-tract-urothelial-cancer\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/urogen-launches-lg-utuc-luminaries-initiative-recognizing-excellence-and-leadership-in-treatment-of-patients-with-low-grade-upper-tract-urothelial-cancer\/","name":"UroGen Launches LG-UTUC Luminaries Initiative Recognizing Excellence and Leadership in Treatment of Patients with Low-Grade Upper Tract Urothelial Cancer - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/urogen-launches-lg-utuc-luminaries-initiative-recognizing-excellence-and-leadership-in-treatment-of-patients-with-low-grade-upper-tract-urothelial-cancer\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/urogen-launches-lg-utuc-luminaries-initiative-recognizing-excellence-and-leadership-in-treatment-of-patients-with-low-grade-upper-tract-urothelial-cancer\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY4NTg0MiM3NTI0MjQ4IzIwMjkwMTk=","datePublished":"2026-04-08T12:07:02+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/urogen-launches-lg-utuc-luminaries-initiative-recognizing-excellence-and-leadership-in-treatment-of-patients-with-low-grade-upper-tract-urothelial-cancer\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/urogen-launches-lg-utuc-luminaries-initiative-recognizing-excellence-and-leadership-in-treatment-of-patients-with-low-grade-upper-tract-urothelial-cancer\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/urogen-launches-lg-utuc-luminaries-initiative-recognizing-excellence-and-leadership-in-treatment-of-patients-with-low-grade-upper-tract-urothelial-cancer\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY4NTg0MiM3NTI0MjQ4IzIwMjkwMTk=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY4NTg0MiM3NTI0MjQ4IzIwMjkwMTk="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/urogen-launches-lg-utuc-luminaries-initiative-recognizing-excellence-and-leadership-in-treatment-of-patients-with-low-grade-upper-tract-urothelial-cancer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"UroGen Launches LG-UTUC Luminaries Initiative Recognizing Excellence and Leadership in Treatment of Patients with Low-Grade Upper Tract Urothelial Cancer"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/949812","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=949812"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/949812\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=949812"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=949812"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=949812"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}